MONTREAL, Feb. 21, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2021 on Monday February 28, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday March 1, 2022 at 8.30am (ET).
|
Conference ID:
|
94559410
|
|
Date:
|
Tuesday, March 1, 2022
|
|
Time:
|
8:30am ET
|
|
Dial-in numbers:
|
1-888-664-6392 or 416-764-8659
|
|
Audio replay numbers:
|
1-888-390-0541 or 416-764-8677
|
|
Replay code:
|
559410#
|
A live audio webcast of the conference call will be available via: https://produceredition.webcasts.com/starthere.jsp?ei=1528479&tp_key=5ba0d2c6d7
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Valeo Pharma Inc.
View original content: http://www.newswire.ca/en/releases/archive/February2022/21/c1483.html